Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $242

Benzinga Newsdesk www.benzinga.com Positive 68.8%

Neg 0% Neu 0% Pos 68.8%

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $217 to $242.